1. Home
  2. IMMR vs SKYE Comparison

IMMR vs SKYE Comparison

Compare IMMR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMR
  • SKYE
  • Stock Information
  • Founded
  • IMMR 1993
  • SKYE 2012
  • Country
  • IMMR United States
  • SKYE United States
  • Employees
  • IMMR N/A
  • SKYE N/A
  • Industry
  • IMMR Computer peripheral equipment
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMMR Technology
  • SKYE Health Care
  • Exchange
  • IMMR Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • IMMR 310.3M
  • SKYE 176.8M
  • IPO Year
  • IMMR 1999
  • SKYE N/A
  • Fundamental
  • Price
  • IMMR $12.14
  • SKYE $5.89
  • Analyst Decision
  • IMMR Strong Buy
  • SKYE Strong Buy
  • Analyst Count
  • IMMR 1
  • SKYE 4
  • Target Price
  • IMMR $11.00
  • SKYE $19.25
  • AVG Volume (30 Days)
  • IMMR 737.2K
  • SKYE 386.3K
  • Earning Date
  • IMMR 08-09-2024
  • SKYE 01-01-0001
  • Dividend Yield
  • IMMR 1.48%
  • SKYE N/A
  • EPS Growth
  • IMMR 33.01
  • SKYE N/A
  • EPS
  • IMMR 1.37
  • SKYE N/A
  • Revenue
  • IMMR $70,692,000.00
  • SKYE N/A
  • Revenue This Year
  • IMMR $107.91
  • SKYE N/A
  • Revenue Next Year
  • IMMR N/A
  • SKYE N/A
  • P/E Ratio
  • IMMR $8.86
  • SKYE N/A
  • Revenue Growth
  • IMMR 84.93
  • SKYE N/A
  • 52 Week Low
  • IMMR $5.94
  • SKYE $1.44
  • 52 Week High
  • IMMR $13.32
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • IMMR 78.07
  • SKYE 34.36
  • Support Level
  • IMMR $9.42
  • SKYE $5.95
  • Resistance Level
  • IMMR $13.32
  • SKYE $6.83
  • Average True Range (ATR)
  • IMMR 0.50
  • SKYE 0.82
  • MACD
  • IMMR 0.23
  • SKYE 0.09
  • Stochastic Oscillator
  • IMMR 70.79
  • SKYE 21.26

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: